Vivanza Biosciences Ltd.

As of June 30, 2026, Vivanza Biosciences Ltd. carries a market capitalization of 72.80M, placing it among publicly traded companies globally. Its enterprise value stands at 72.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Vivanza Biosciences Ltd. has 40.00M shares outstanding.

As of June 30, 2026, Vivanza Biosciences Ltd. trades at a trailing price-to-earnings ratio of 15.72.

As of June 30, 2026, Vivanza Biosciences Ltd. trades at an EV/EBITDA multiple of 14.42 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.13 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 72.80M versus a market cap of 72.80M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 166.09M in revenue per employee across its workforce of 7.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Vivanza Biosciences Ltd. recorded 1.85M in income tax expense. That works out to an effective tax rate of 28.94, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 6.39M, leaving 4.54M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Vivanza Biosciences Ltd.'s stock has declined approximately 21.95% over the past 52 weeks. The 50-day moving average sits at 1.76, while the 200-day moving average is 1.91.

Over the twelve months ended June 30, 2026, Vivanza Biosciences Ltd. generated 1.16B in revenue and converted that into 4.54M in net income, yielding earnings per share of 0.12. EBITDA reached 5.05M, while operating income came in at 4.81M.

Over the twelve months ended June 30, 2026, Vivanza Biosciences Ltd. posted a gross margin of 1.00, reflecting its pricing power and cost economics. The operating margin of 0.41 and net profit margin of 0.39 provide insight into operational efficiency.

Vivanza Biosciences Ltd.'s most recent stock split took place on March 27, 2023 with a 1:10 split ratio.